Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Neurology | Psychiatry/Psychology | Pediatrics/Neonatology
Disease Category: Attention Deficit/Hyperactivity Disorder (ADHD - Pediatric)
Trial Information
Measuring and Predicting Response to Atomoxetine and Methylphenidate
Attention Deficit/Hyperactivity Disorder (ADHD) is one of the
most frequently occurring disorders of children and adolescents,
and represents a significant public health problem. There are
several different medication treatment options and this study will
compare two medications that are commonly prescribed. All
participants will have the opportunity to try each medication. Both
medications are appproved treatments by the Food and Drug
Administration (FDA). All participants will be evaluated for ADHD
and other conditions. Evaluations and medication provided at no
cost.
Compensation Provided
Patient Inclusion/Exclusion Criteria:
Have ADHD or undiagnosed ADHD (easliy distracted, forgetful,
disorganized...).
Ages 7-17.
In good health.
Able to swallow pills.
Able to attend weekly visits.
Cannot participate if have had bad reactions to Strattera or
Concerta.
Ms. Robyn C Palmero, M.A.
Mount Sinai Medical Center
One Gustave L. Levy Place
New York, NY 10029
Phone: 877-ADHD-411
Fax: 212-849-2690
EMail: robyn.palmero@mssm.edu
View Google Map
If you would like to learn more about participating in this study, please send an e-mail message using the form below.
DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the
clinical trials industry. The information provided in this service is designed
to help patients find clinical trials that may be of interest to them, and to
help patients contact the centers conducting the research. CenterWatch is
neither promoting this research nor involved in conducting any of these
trials.
